Document is current
Any future updates will be listed below
-
Authors
Melgaard, Line
Nielsen, Peter Brønnum
Overvad, Thure Filskov
Skjøth, Flemming
Lip, Gregory Y. H.
Larsen, Torben Bjerregaard
-
Funding
Funding for this research was provided by:
Det Obelske Familiefond (N/A)
- License Information
-
More Information
Article History
Received: 1 March 2018
Accepted: 16 July 2018
First Online: 21 August 2018
Compliance with ethical standards
:
: Professor Lip: Consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. Associate Professor Larsen: An investigator for Janssen Scientific Affairs, LLC, and Boehringer Ingelheim. Speaker for Bayer, BMS/Pfizer, Janssen Pharmaceuticals, Takeda, Roche Diagnostics, and Boehringer Ingelheim. Peter Brønnum Nielsen: Speaker for Boehringer Ingelheim and Bayer Pharma AG; research Grant from BMS/Pfizer. Flemming Skjøth: Consultancy fees from Bayer. Other authors—none declared. Profs Lip and Larsen are guarantors of this paper.
